drugset / Trial / NCT05124210
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (\<)18 years old with mild-to-moderate Coronavirus Disease-2019 (COVID-19) at high risk of disease progression.
Timeline
- Start
- 2021-12-16
- Primary completion
- 2023-06-14
- Completion
- 2023-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sotrovimab | Monoclonal antibody | 500 mg | Intravenous |